Cardiac Imaging

While cardiac ultrasound is the widely used imaging modality for heart assessments, computed tomography (CT), magnetic resonance imaging (MRI) and nuclear imaging are also used and are often complimentary, each offering specific details about the heart other modalities cannot. For this reason the clinical question being asked often determines the imaging test that will be used.

A structural heart Presentation during the TVT 2022 conference. #TCT #TCT22 #TCT2022

TCT 2022 late-breaking clinical presentations announced

The Cardiovascular Research Foundation (CRF) announced the 32 late-breaking studies being presented at the Transcatheter Cardiovascular Therapeutics 2022 annual meeting at in Boston, Sept. 16-19.

Thumbnail

1 in 20 hospitalized COVID-19 patients develop new-onset AFib

Researchers examined data from nearly 31,000 adult patients hospitalized with COVID-19, sharing their findings in Circulation: Arrhythmia and Electrophysiology.

VIDEO: Gender differences in women with cardiovascular disease and implications for imagers

Erin D. Michos, MD, co-editor in chief of the American Journal of Preventive Cardiology, discusses gender differences in heart disease presentations.

Thumbnail

HFpEF patients with MR may face a higher mortality risk—but not if they have AFib

There is an established connection between MR and HFrEF, but we know much less about the link between MR and HFpEF. 

Comparison of flurpiridaz F-18 PET, SPECT and angiography of the 60-year-old female patients in the Aurora trial. The SPECT scan appeared normal, but flurpiridaz was shown to be more sensitive and showed the ischemia from two blockages in the right coronary artery. The new radiotracer may help expand cardiac PET. #ASNC

Flurpiridaz data shows promise to expand and enhance cardiac PET

The biggest news from the American Society of Nuclear Cardiology (ASNC) 2022 meeting was positive late-breaking data on the phase 3 Aurora trial for the flurpiridaz (F-18) PET radiotracer agent.

Three transcatheter tricuspid valve repair and replacement (TTVR) technologies that will likely see FDA clearance in. the next couple years include the Edwards Evoque transcatheter tricuspid valve (top left), Abbott TriClip (below) and the Edwards Lifesciences Pascal clip device (right).

Tricuspid valve therapies moving ahead of mitral therapies seeking market approval

The complexity of the mitral valve has slowed development of new transcatheter technologies, and it now seems much more likely that transcatheter devices for tricuspid valve will push ahead to gain FDA clearances.

Thermedical SERF thermal ablation system for VT.

FDA approves trial for new type of thermal-ablation system to treat ventricular arrhythmias

The FDA has approved a clinical trial to evaluate the safety and efficacy of a new type of ablation catheter for patients with ventricular tachycardia (VT) resistant to conventional anti-arrhythmic drugs or standard ablation procedures.

Interview with Rebecca T. Hahn, MD, Professor of Medicine at Columbia University Irving Medical Center, Chief Scientific Officer of the Echo Core Lab at the Cardiovascular Research Foundation and Director of Interventional Echocardiography at the Columbia Structural Heart and Valve Center. She discusses some of the trends of growing use of interventional echocardiographic guidance in transcatheter structural heart procedures, the growing number of tricuspid valve procedures, and use of 3D ICE.

VIDEO: Trends in structural heart procedural imaging - a discussion with Rebecca Hahn

Rebecca T. Hahn, MD, Director of Interventional Echocardiography at the Columbia Structural Heart and Valve Center, discusses some of the trends in the growing use of interventional echocardiographic guidance in transcatheter structural heart procedures.

Around the web

Ron Blankstein, MD, professor of radiology, Harvard Medical School, explains the use of artificial intelligence to detect heart disease in non-cardiac CT exams.

Eleven medical societies have signed on to a consensus statement aimed at standardizing imaging for suspected cardiovascular infections.